Morgan Stanley lowered the firm’s price target on Mondelez (MDLZ) to $71 from $73 and keeps an Overweight rating on the shares. The firm, which is lowering estimates to reflect recent scanner data trends in the U.S. and Western Europe and company commentary, now forecasts FY25 organic sales growth of 4.2%, down from 5.4% projected previously.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLZ:
- Mondelez International: Strategic Adjustments and Cost Reductions Support Buy Rating Amid Short-Term Challenges
- Berkshire to acquire OxyChem, OpenAI reaches $500B valuation: Morning Buzz
- Nike upgraded, RH downgraded: Wall Street’s top analyst calls
- Mondelez downgraded to Hold from Buy at Berenberg
- Mondelez praised by RFK Jr. for switching to natural food dyes